Table 4.
The patients’ characteristics in different groups of PD-L1 expression levels (n = 71).
| Characteristics | PD-L1 expression level | P value* | |
|---|---|---|---|
| ≧50%, n (%) | < 50%, n (%) | ||
| Age | 0.708 | ||
| ≧65 | 4 (50.0) | 25 (39.7) | |
| < 65 | 4 (50.0) | 38 (60.3) | |
| Gender, n (%) | 0.708 | ||
| Male | 4 (50.0) | 25 (39.7) | |
| Female | 4 (50.0) | 38 (60.3) | |
| Smoking status, n (%) | 1.000 | ||
| Never-smokers | 6 (75.0) | 42 (66.7) | |
| Former or current-smokers | 2 (25.0) | 21 (33.3) | |
| ECOG PS, n (%) | 0.133 | ||
| 0–1 | 6 (75.0) | 59 (93.7) | |
| 2–3 | 2 (25.0) | 4 (6.3) | |
| Stage, n (%) | 1.000 | ||
| Post-operation recurrence | 1 (12.5) | 10 (15.9) | |
| Stage 4A | 3 (37.5) | 24 (38.1) | |
| Stage 4B | 4 (50.0) | 29 (46.0) | |
| Brain metastasis at baseline, n (%) | 0.708 | ||
| Yes | 3 (37.5) | 20 (31.7) | |
| No | 5 (62.5) | 43 (68.3) | |
| Baseline EGFRmutation status, n (%) | 1.000 | ||
| Exon 19 deletion | 6 (75.0) | 46 (73.0) | |
| Exon 21 L858R | 2 (25.0) | 17 (27.0) | |
PD-L1, Programmed death-ligand 1; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor.
*By Fisher's exact test.